Table of Contents
ISRN Oncology
Volume 2012 (2012), Article ID 896202, 5 pages
http://dx.doi.org/10.5402/2012/896202
Clinical Study

Evaluation of Acute Locoregional Toxicity in Patients with Breast Cancer Treated with Adjuvant Radiotherapy in Combination with Pazopanib

Department of Radiation Oncology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, UMDNJ 195 Little Albany Street, New Brunswick, NJ 08903, USA

Received 28 September 2012; Accepted 31 October 2012

Academic Editors: R. Addeo and Y. Yamamoto

Copyright © 2012 Sharad Goyal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Karar and A. Maity, “Modulating the tumor microenvironment to increase radiation responsiveness,” Cancer Biology and Therapy, vol. 8, no. 21, pp. 1994–2001, 2009. View at Google Scholar · View at Scopus
  2. P. Vaupel and L. Harrison, “Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response,” The Oncologist, vol. 9, supplement 5, pp. 4–9, 2004. View at Google Scholar · View at Scopus
  3. P. Vaupel, “Tumor microenvironmental physiology and its implications for radiation oncology,” Seminars in Radiation Oncology, vol. 14, no. 3, pp. 198–206, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. P. E. Huber, M. Bischof, J. Jenne et al., “Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy,” Cancer Research, vol. 65, no. 9, pp. 3643–3655, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. R. K. Jain, “Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy,” Science, vol. 307, no. 5706, pp. 58–62, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. F. A. B. Schutz, T. K. Choueiri, and C. N. Sternberg, “Pazopanib: clinical development of a potent anti-angiogenic drug,” Critical Reviews in Oncology/Hematology, vol. 77, no. 3, pp. 163–171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Nieder, N. Wiedenmann, N. Andratschke, and M. Molls, “Current status of angiogenesis inhibitors combined with radiation therapy,” Cancer Treatment Reviews, vol. 32, no. 5, pp. 348–364, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Goyal, M. S. Rao, A. Khan, L. Huzzy, C. Green, and B. G. Haffty, “Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab,” International Journal of Radiation Oncology Biology Physics, vol. 79, no. 2, pp. 408–413, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. F. A. B. Schutz, T. K. Choueiri, and C. N. Sternberg, “Pazopanib: clinical development of a potent anti-angiogenic drug,” Critical Reviews in Oncology/Hematology, vol. 77, no. 3, pp. 163–171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Albiges, M. Salem, B. Rini, and B. Escudier, “Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma,” Hematology/Oncology Clinics of North America, vol. 25, no. 4, pp. 813–833, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Sideras, M. E. Menefee, J. K. Burton, C. Erlichman, K. C. Bible, and S. P. Ivy, “Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib,” Journal of Clinical Oncology, vol. 28, no. 19, pp. e312–e313, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Katayama, M. Ashida, A. Maeda, K. Eishi, H. Murota, and S. J. Bae, “Open trial of topical tacalcitol [1α24(OH)2D3] and solar irradiation for vitiligo vulgaris: upregulation of c-Kit mRNA by cultured melanocytes,” European Journal of Dermatology, vol. 13, no. 4, pp. 372–376, 2003. View at Google Scholar · View at Scopus
  13. N. S. Vasudev and J. M. G. Larkin, “Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib,” Clinical Medicine Insights, vol. 5, pp. 333–342, 2011. View at Publisher · View at Google Scholar · View at Scopus